TO THE EDITOR
Dr Laporte and colleagues recently described in Leukemia (September 2004, Vol 18, No. 9) an adult acute lymphoid leukemia (ALL) patients early relapsed after standard chemotherapy, and treated with alemtuzumab (campath 1H, Mab Campath, Schering AG, Germany).
1 Alemtuzumab was administered at a dose of 30 mg, 3 days a week for 4 weeks, and then at a dose of 30 mg, 3 days a week every 2 months as maintenance, in association with G-CSF and erythropoietin (EPO). Notably, the patient achieved a long-lasting cytogenetic complete remission (CR), although without a complete recovery of the peripheral blood counts. 1 Some months ago, we reported, for the first time to the best of our knowledge, the first three ALL patients treated with alemtuzumab. 2 In the past, only a rat IgG2b anti-CD52 and not the humanized form had been used for the treatment of ALL. 3 All our three patients were relapsed after stem cell transplantation and were then treated with campath-1 H as compassionate, not being suitable to receive conventional therapy. 2 Alemtuzumab was administered alone at a dose of 30 mg every other day, for five doses in all the cases. No other therapy, including cytokines, was associated. All the three patients showed a clinical response, but no one obtained a CR. In particular, in one case we observed a significant reduction in bone marrow blasts, in one case a complete clearance of the peripheral blood blasts, and in one case a significant reduction of the spleen size. 2 All the three patients then died within few months for progressive leukemia.
There are some differences between the therapeutic schedules which Laporte and colleagues and we used. First, they administered 12 doses of alemtuzumab as 'induction' of remission, whereas we administered only five doses. The total amount of administered drug may have played a significant role for the induction of a complete remission. Secondly, they also dispensed alemtuzumab as a maintenance therapy, a scheme recently shown to be effective in chronic lymphocytic leukemia. 4 Finally, they associated to the monoclonal antibody some cytokines such as EPO and, in particular, G-CSF, whose additive effect cannot be excluded. Nonetheless, it should be considered that our patients had already received at least three lines of therapy, including autologous or allogeneic bone marrow transplantation, and presented with very advanced disease. 2 We conclude that alemtuzumab looks promising for the therapy of acute lymphoid leukemia, but further studies are warranted in order to define the best treatment schedule and eventually its definitive role in this setting.
